共 42 条
- [1] A FIRST-IN-HUMAN PHASE I DOSE-ESCALATION TRIAL OF THE B7-H6/CD3 T-CELL ENGAGER BI 765049 ± EZABENLIMAB (BI 754091) IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING B7-H6JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A510 - A510Falchook, GeraldSpigel, DavidPatel, ManishBashir, BabarUlahannan, SusannaDuffy, ChristineMaier, DanielaAzuma, Hisaya
- [2] A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Doi, ToshihikoYamamoto, NoboruKitano, ShigehisaLatek, RobertHou, JianruiTanaka, Yuko
- [3] TRIAL IN PROGRESS: PHASE I DOSE-ESCALATION STUDY OF VSV-GP (BI 1831169) MONOTHERAPY AND WITH EZABENLIMAB (BI 754091) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A660 - A660Porosnicu, MercedesQuinson, Anne-MarieMacKay, AbiLuecke, StephanLauer, Ulrich M.
- [4] A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Li, FengLiu, MingHua, YananWei, XuemeiQin, LuyingCao, GuangcanYang, Daniel ChunxuZhang, Wenjun
- [5] A novel B7-H6/CD3 bispecific IgG-like T cell engaging antibody for the treatment of colorectal cancer.CANCER RESEARCH, 2021, 81 (13)Hipp, SusanneZhang, WeiLiao, XiaoyunAuguste, AurelieOsswald, AnnikaBauer, KathrinWalterskirchen, ChristianSayedian, Farzaneh H.Kellner, ManuelaGiragossian, CraigVoynov, VladimirNixon, Andrew E.Adam, Paul J.
- [6] A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Richardson, Gary EdwardKichenadasse, GanessanZorko, NicholasMa, Wen WeeChen, HuiziStarks, DavidSutherland, SarahKamasani, SujanaKhot, AntariMa, XinTrepicchio, William L.Zhang, YefeiAhern, Elizabeth Stephanie
- [7] First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S336 - S336Wu, J.Zhang, J.Li, H.Wang, X.Zhang, Q. Y.Shi, Y.Yan, M.Pan, Y.Shen, A.Chen, Q.Rao, Q.Wei, H.Li, C.Yang, L.Huang, Q.Cao, Z.Wu, Q.
- [8] A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR 3 CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S492 - S492Weickhardt, A. J.Frentzas, S.Lemech, C.Srimani, J.Yin, J.Trepicchio, W. L.Gorgun, C.Kichenadasse, G.
- [9] Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculatureJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Tolcher, Anthony W.Alley, Evan W.Chichili, GuruBaughman, Jan E.Moore, Paul A.Bonvini, EzioVasselli, James RobertWigginton, Jon M.Powderly, John D.
- [10] Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+Tumors: Focus on SCLCJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S45 - S46Wermke, M.Kuboki, Y.Felip, E.Alese, O. B.Morgensztern, D.Sayehli, C.Arriola, E.Sanmamed, M. F.Oum'Hamed, Z.Song, E.Studeny, M.Gambardella, V.